CBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
CRESCENT BIOPHARMA, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$12.36+0.52 (+4.39%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.18 (−1.44%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CRESCENT BIOPHARMA, INC. reported revenue of $10.84M for fiscal 2025. Free cash flow was -$73.62M.
Revenue
$10.84M
FY2025
Operating income
-$168.47M
TTM Q2 2026
Free cash flow
-$73.62M
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $10.84M
- Net income
- -$96.03M
- Free cash flow
- -$73.62M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$168.47M
Net income
-$96.03M
EPS, diluted
–
Free cash flow
-$73.62M
Reported periodTrailing twelve months